An Open-Label, Safety, Pharmacokinetic and Pharmacodynamic Study of Multiple Doses of GW786034 and Lapatinib Concomitantly Administered in Cancer Patients
Latest Information Update: 31 Aug 2023
Price :
$35 *
At a glance
- Drugs Lapatinib (Primary) ; Pazopanib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 15 Oct 2008 Actual start date changed from Oct 2004 to Sep 2004 as reported by Clinicaltrials.gov.
- 20 Aug 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 10 Jul 2007 Status changed from recuiting to in progress.